PubRank

S Rose-John

Author PubWeight™ 150.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000 6.68
2 Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001 3.27
3 I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997 2.47
4 Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001 2.30
5 The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994 2.26
6 Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996 2.19
7 The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993 2.01
8 Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006 1.95
9 Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992 1.94
10 Structure of an extracellular gp130 cytokine receptor signaling complex. Science 2001 1.94
11 IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005 1.79
12 A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995 1.70
13 TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999 1.69
14 The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996 1.65
15 An evaluation of 2,5-norbornadiene as a reversible inhibitor of ethylene action in deepwater rice. Plant Physiol 1987 1.60
16 Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A 1998 1.51
17 Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 1998 1.50
18 Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998 1.32
19 Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 2000 1.32
20 STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006 1.30
21 Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology 1996 1.26
22 Development of a human interleukin-6 receptor antagonist. J Biol Chem 1994 1.25
23 The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 2000 1.21
24 In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 1998 1.19
25 Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 1998 1.19
26 Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 1993 1.18
27 Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain 2005 1.15
28 Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997 1.13
29 Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999 1.12
30 Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999 1.11
31 Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999 1.10
32 Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc Natl Acad Sci U S A 2001 1.10
33 Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett 1993 1.10
34 Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 2000 1.09
35 Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol 1994 1.09
36 Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect Immun 1996 1.05
37 Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes. FEBS Lett 1992 1.05
38 Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. J Immunol 1991 1.04
39 The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 1997 1.04
40 IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol 2000 1.03
41 The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett 1992 1.03
42 Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000 1.03
43 Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A 1996 1.02
44 TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol 1997 1.02
45 Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J 2001 1.02
46 Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun 1992 1.01
47 IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 1999 1.01
48 The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem 1999 1.00
49 Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 2000 0.99
50 Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med 1994 0.99
51 Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur J Biochem 1994 0.98
52 Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells. Eur J Biochem 2000 0.98
53 Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6. J Biol Chem 1999 0.97
54 Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. J Biol Chem 1994 0.97
55 Introduction to stem cell biology in vitro. Threshold to the future. Ann N Y Acad Sci 1999 0.97
56 Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol 1997 0.96
57 Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. Eur J Biochem 1993 0.96
58 The induction of ornithine decarboxylase by the tumor promoter TPA is controlled at the post-transcriptional level in murine Swiss 3T3 fibroblasts. Biochem Biophys Res Commun 1987 0.96
59 Soluble interleukin 6 receptor is biologically active in vivo. Cytokine 1995 0.96
60 Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Eur J Biochem 1995 0.96
61 Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J Immunol 1998 0.96
62 TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. FEBS Lett 1994 0.92
63 Cytokines and neurotrophins interact in normal and diseased states. Ann N Y Acad Sci 2000 0.92
64 Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 2010 0.91
65 Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Ther 2001 0.91
66 Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. J Immunol 1997 0.90
67 Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. J Neurosci Res 1999 0.90
68 Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin Exp Immunol 2002 0.90
69 The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett 1995 0.90
70 The membrane proximal cytokine receptor domain of the human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association. J Biol Chem 1998 0.89
71 The IL-6/sIL-6R fusion protein hyper-IL-6 promotes neurite outgrowth and neuron survival in cultured enteric neurons. J Interferon Cytokine Res 1999 0.89
72 Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 1997 0.89
73 Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production. Immunol Lett 2000 0.89
74 Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol 2001 0.89
75 A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding. Eur J Biochem 1999 0.88
76 Structure-function analysis of human interleukin-6. Evidence for the involvement of the carboxy-terminus in function. FEBS Lett 1990 0.88
77 Soluble human interleukin-6-receptor modulates interleukin-6-dependent N-glycosylation of alpha 1-protease inhibitor secreted by HepG2 cells. FEBS Lett 1992 0.88
78 Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J Immunol 2000 0.87
79 The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001 0.87
80 Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett 1992 0.87
81 A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1). FEBS Lett 1995 0.86
82 Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6. FEBS Lett 1991 0.86
83 Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor beta 1. FEBS Lett 1992 0.86
84 Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Lett 1995 0.85
85 The function of the soluble IL-6 receptor in vivo. Immunol Lett 1996 0.85
86 The three carboxy-terminal amino acids of human interleukin-6 are essential for its biological activity. FEBS Lett 1990 0.85
87 Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived epithelial cells. Biochem J 1998 0.85
88 Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. Eur J Neurosci 1997 0.85
89 Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 1988 0.85
90 Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro. Exp Hematol 2001 0.84
91 Combining two mutations of human interleukin-6 that affect gp130 activation results in a potent interleukin-6 receptor antagonist on human myeloma cells. J Biol Chem 1995 0.84
92 Rapid differentiation of a rare subset of adult human lin(-)CD34(-)CD38(-) cells stimulated by multiple growth factors in vitro. Blood 1999 0.84
93 In vitro reconstitution of recognition and activation complexes between interleukin-6 and gp130. Biochemistry 2001 0.84
94 Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virology 2000 0.84
95 TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia 2009 0.83
96 Molecular cloning and expression of an intracellular serpin: an elastase inhibitor from horse leucocytes. Biochem J 1993 0.83
97 Astrocytic alterations in interleukin-6/Soluble interleukin-6 receptor alpha double-transgenic mice. Am J Pathol 2000 0.83
98 The SLAM family member CD84 is regulated by ADAM10 and calpain in platelets. J Thromb Haemost 2012 0.83
99 Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 1999 0.83
100 Membrane-bound and soluble interleukin-6 receptor: studies on structure, regulation of expression, and signal transduction. Ann N Y Acad Sci 1995 0.82
101 Residues 77-95 of the human interleuken-6 protein are responsible for receptor binding and residues 41-56 for signal transduction. Ann N Y Acad Sci 1995 0.82
102 Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J 1991 0.82
103 Gp130-signaling synergizes with FL and TPO for the long-term expansion of cord blood progenitors. Leukemia 1999 0.82
104 Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. J Interferon Cytokine Res 1996 0.82
105 The therapeutic potential of interleukin-6 hyperagonists and antagonists. Expert Opin Investig Drugs 1997 0.82
106 Up- and down-regulation of granulocyte/macrophage-colony stimulating factor activity in murine skin increase susceptibility to skin carcinogenesis by independent mechanisms. Cancer Res 2001 0.82
107 Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes. Cytokine 1998 0.81
108 Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)-binding sites of the human IL-6 receptor. Eur J Biochem 1996 0.81
109 ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis 2014 0.81
110 Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling. Br J Cancer 2007 0.80
111 A new type of cytokine receptor antagonist directly targeting gp130. J Biol Chem 1998 0.80
112 The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp Hematol 2000 0.80
113 Effect of soluble interleukin-6 receptor on interleukin-6 synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1996 0.80
114 cDNA-cloning, sequencing and expression in glucocorticoid-stimulated quiescent Swiss 3T3 fibroblasts of mouse lipocortin I. Biochem Biophys Res Commun 1989 0.80
115 Yeast expression of the cytokine receptor domain of the soluble interleukin-6 receptor. J Immunol Methods 1996 0.80
116 New perspectives on the design of cytokines and growth factors. Trends Biotechnol 2000 0.80
117 Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther 2012 0.80
118 The hepatic interleukin-6 receptor. Studies on its structure and regulation by phorbol 12-myristate 13-acetate-dexamethasone. J Biol Chem 1993 0.80
119 Functional distinction of two regions of human interleukin 6 important for signal transduction via gp130. Cytokine 1995 0.80
120 Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995 0.80
121 Possible role of human interleukin-6 and soluble interleukin-6 receptor in hepatitis B virus infection. J Viral Hepat 2001 0.79
122 Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. Eur Cytokine Netw 1997 0.79
123 Expression of a biologically active murine tissue inhibitor of metalloproteinases-1 (TIMP-1) in baculovirus-infected insect cells. Purification and tissue distribution in the rat. Eur J Biochem 1995 0.79
124 Human CNTF and related cytokines: effects on DRG neurone survival. Neuroreport 1995 0.79
125 Microheterogeneity of human interleukin 6 synthesized by transfected NIH/3T3 cells: comparison with human monocytes, fibroblasts and endothelial cells. Eur J Immunol 1990 0.78
126 Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets. J Biol Regul Homeost Agents 2013 0.78
127 Alternative assay procedures for cytokines and soluble receptors of the IL-6 family. J Immunol Methods 1996 0.78
128 gp130-stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. Exp Hematol 2001 0.78
129 Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectin. Blood 2000 0.78
130 Generation and function of the soluble interleukin-6 receptor. Biochem Soc Trans 1999 0.78
131 Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors. Leukemia 2002 0.78
132 Interleukin-6-type cytokines and their receptors for gene therapy of melanoma. Ann N Y Acad Sci 1995 0.78
133 Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells. FEBS Lett 1998 0.78
134 Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. J Immunol 1997 0.78
135 Expression of the kinase domain of mouse protein kinase C in E. coli. Biochem Int 1989 0.77
136 Identification of residues in the putative 5th helical region of human interleukin-6, important for activation of the IL-6 signal transducer, gp130. FEBS Lett 1996 0.77
137 Interferon-gamma regulates alpha 2-macroglobulin and alpha 1-antichymotrypsin expression on the pretranslational level in HepG2 cells. Folia Histochem Cytobiol 1992 0.77
138 Recombinant human single chain Fv antibodies recognizing human interleukin-6. Specific targeting of cytokine-secreting cells. J Biol Chem 1998 0.77
139 Site-directed mutagenesis of human CNTF: functional analysis of recombinant variants. J Neurosci Res 1995 0.77
140 Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130. FEBS Lett 1995 0.77
141 Signals regulating neurotrophin expression in glial cells. Prog Brain Res 2001 0.76
142 Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000 0.76
143 [Cytokines: biology and therapeutic relevance]. Dtsch Med Wochenschr 1996 0.75
144 Immunogene therapy of human melanoma. Phase I/II clinical trial. Adv Exp Med Biol 1998 0.75
145 TIMP-1 protein expression is stimulated by IL-1 beta and IL-6 in primary rat hepatocytes. Ann N Y Acad Sci 1995 0.75
146 A novel and rapid prediction assay for the effectiveness of IL-6 receptor specific antisense oligonucleotides by proliferation inhibition of an interleukin-6 dependent cell line. Cell Biol Int 2001 0.75
147 Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. J Immunol Methods 1999 0.75
148 New developments in IL-6 dependent biology and therapy: where do we stand and what are the options? Expert Opin Investig Drugs 1999 0.75
149 Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Adv Exp Med Biol 2001 0.75
150 Biosynthesis and distribution of leucocyte elastase inhibitor. Production of recombinant inhibitor. Acta Biochim Pol 1996 0.75
151 Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing. J Interferon Cytokine Res 1998 0.75
152 An IL-6/IL-6 soluble receptor (IL-6R) hybrid protein (H-IL-6) induces EPO-independent erythroid differentiation in human CD34(+) cells. Cytokine 2000 0.75
153 A region within the cytoplasmic domain of the interleukin-6 signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor. Ann N Y Acad Sci 1995 0.75
154 More about genetically modified tumour vaccines. Gene Ther 1998 0.75